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Purpose: Age-related macular degeneration (AMD) is the leading cause of blindness in elderly. The detailed mechanism
of choroidal neovascularization (CNV) leads to severe vision loss in patients with AMD. This study was undertaken to
evaluate the inhibitory effect of homoisoflavanone on CNV.
Methods: Antiangiogenic activity of homoisoflavanone was evaluated by in vitro tube formation assay of human umbilical
vein  endothelial  cells  (HUVECs)  and  cell  migration  assay  of  HUVECs.,  Homoisoflavanone  or  PBS  was  injected
intravitreously into a mouse model of laser-photocoagulation-induced CNV. Fluorescein angiography and vessel counting
in cross sections were employed to examine CNV lesions. The toxicity of homoisoflavanone was evaluated through 3-
(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay (MTT) assay in HUVECs as well as histological
examination and terminal deoxynucleotidyl transferase biotin-dUTP nick end labeling (TUNEL) staining in the retina.
Results: Homoisoflavanone effectively inhibited in vitro tube formation and cell migration of HUVECs. Interestingly,
homoisoflavanone significantly reduced CNV and its leakage in a mouse model of laser-photocoagulation-induced CNV.
In addition, homoisoflavanone showed no effect on cell viability of HUVECs and no retinal toxicity in a concentration
range of 1-10 μM.
Conclusions: Our data suggest that homoisoflavanone is a potent inhibitor of CNV and may be applied in the treatment
of other vasoproliferative retinopathies and tumor.
Angiogenesis is a process that forms new blood vessels;
it  is  tightly  regulated  by  a  balance  between  positive  and
negative factors [1]. Normally, it does not occur except during
developmental or vessel repair. Pathological angiogenesis in
the eye is the most common cause of blindness in all age
groups. For example, retinopathy of prematurity (ROP) is the
common cause for children, diabetic retinopathy for young
adults, and age-related macular degeneration for elderly [2].
In developed countries, AMD is the leading cause of
blindness  in  adults  55  years  and  older  [3].  Choroidal
neovascularization (CNV) can lead to severe vision loss in
patients  with  AMD  [4].  CNV  occurs  through  vessel
proliferation  from  the  choroidal  vessels  invading  the
subretinal  space  after  the  rupture  of  Bruch’s  membrane
followed by the vessel proliferation from the choroidal vessels
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invading the subretinal space. CNV vessels are fragile and
leaky,  leading  to  hemorrhage  or  exudation,  which  injures
photoreceptor cells. Further, these proliferative vessels induce
the  formation  of  fibrovascular  scarring,  which  results  in
irreversible  damage  to  retinal  function  and  can  lead  to
blindness [5]. Since excessive proliferation of vascular cells
is the essential mechanism of CNV, a reasonable therapeutic
approach is to directly suppress the proliferating vascular
endothelial cells.
The homoisoflavonone, 5,7-dihydroxy-3-(3-hydroxy-4-
methoxybenzyl)-6-methoxychroman-4-1,  was  found  in  the
bulb of Cremastra appendiculata which has been traditionally
known as a medicinal plant in East Asia. We determined that
homoisoflavanone is a potent angiogenesis inhibitor in the
course of our research for new angiogenesis inhibitors from
natural  products  [7].  Moreover,  we  showed  that
homoisoflavanone inhibits retinal neovascularization, which
is related to G2/M phase cell cycle arrest with increase of
p21WAF1 expression [8].
The most common model of CNV is created by laser-
photocoagulation-induced  rupture  of  Bruch’s  membrane,
which  stimulates  neovascularization  from  preexisting
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556choroidal capillary networks [6]. In the present study, we
demonstrate homoisoflavanone inhibits in vitro angiogenesis
of human umbilical vein endothelial cells (HUVECs) without
cytotoxic effect under therapeutic concentration range of 1-10
μM, and significantly reduces CNV in a laser CNV model
without  significant  retinal  toxicity  on  the  therapeutic
concentration.  Herein,  we  suggest  that  homoisoflavanone
may have therapeutic potential in the treatment of CNV of
AMD as well as in other vasoproliferative retinopathies, such
as retinopathy of prematurity and diabetic retinopathy, and
tumors.
METHODS
Animals:  Female  C57BL/6  mice,  aged  7-  8  weeks,  were
purchased from Samtako (Gyeonggi-do, Korea). Care, use,
and  treatment  of  all  animals  in  this  study  were  in  strict
agreement with the ARVO statement for the Use of Animals
in Ophthalmic and Vision Research.
Preparation  of  homoisoflavanone:  Homoisoflavanone  was
extracted from the bulb of Cremastra appendiculata (Seoul,
Korea) by eluting with ethanol as previously described [7].
The  final  product  was  more  than  99%  pure.
Homoisoflavanone was stored at a stock concentration of
1mM in a nitrogen tank.
Tube  formation  assay:  Tube  formation  was  assayed  as
described previously [9]. The air-dried bulb was milled and
extracted in 85% ethanol, which was filtered and concentrated
under vacuum. The ethanol extract was separated by silica gel
column  chromatography.  HUVECs  (1×105  cells)  were
inoculated on the surface of the Matrigel (Sigma–Aldrich
Ltd., St. Louis, MO), and treated with 1 μM homoisoflavanone
or  fibroblast  growth  factor  (FGF)-2  for  18  h.  The
morphological changes of the cells and tubes formed were
observed under a microscope (Carl Zeiss, Chester, VA) and
photographed at a ×200 magnification. Tube formation was
quantified  by  counting  the  number  of  connected  cells  in
randomly  selected  fields  at  a  ×200  magnification  with  a
microscope, and dividing that number by the total number of
cells in the same field.
Endothelial cell migration assay: Chemotactic motility of
HUVECs was assayed as described previously [9]. Briefly,
the lower surface of the filter was coated with gelatin. One
hundred microliters of the cell suspension was loaded into
each of the upper wells, and the chamber was incubated at 37
°C for 4 h. The cells were fixed and stained with hematoxylin
and eosin. Nonmigrating cells on the upper surface of the filter
were removed by wiping with a cotton swab. The migration
assay of endothelial cells was performed in vitro using a
Transwell  chamber  system  with  8.0  μm  pore-sized
polycarbonate  filter  inserts  (Corning  Costar,  Cambridge,
MA). The total number of migrated cells in the lower side of
the  filter  was  quantified  at  a  ×200  magnification  with  a
microscope(Carl Zeiss, Chester, VA). Ten fields were counted
for each assay.
Cell viability assay: Cell viability was evaluated with the 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium  bromide
(MTT) assay. HUVECs (1x105 cells) were plated in 96-well
plates and cultured overnight. Cells were treated with 1-10
μM  homoisoflavanone  for  48  h.  The  medium  was  then
replaced with fresh medium containing 0.5 mg/mL MTT for
4 h. After incubation, the medium was carefully removed from
the  plate,  and  Dimethyl  sulfoxide  (DMSO)  was  added  to
solubilize formazan produced from MTT by the viable cells.
Absorbance  was  measured  at  540  nm  using  a  microplate
reader (Molecular Devices, Sunnyvale, CA).
Laser-photocoagulation-induced  choroidal
neovascularization: Female C57BL/6J mice, aged 7-8 weeks,
were  anesthesized  with  an  intraperitoneal  injection  of
ketamine-xylazine (10 mg/kg), and the pupils were dilated
with 1% tropicamide (Alcon Laboratories Inc., Fort Worth,
TX). The burn of a 831-nm 106 diode laser photocoagulation
(75 μm spot size, 0.1 s duration, 120 mW) was delivered to
each 3, 6, 9, and 12 o’clock position of two disc diameters
from optic disc by using an indirect head set delivery system
of a photocoagulator (OcuLight; Iridex, Mountain View, CA)
and a handheld +78 diopter lens. The bubbling or pop sensing
with laser photocoagulation was considered as the successful
Figure 1. Effect of homoisoflavanone on fibroblast growth factor-2
and  human  umbilical  vein  endothelial  cells.  A:  Each  figure  is
representative  of  three  independent  experiments.  B:  Basal  tube
formation of human umbilical vein endothelial cells (HUVECs) left
in serum-free media was normalized to 100% respectively. Each
value represents means ± SEM from three independent experiments
(*p<0.05).
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557rupture of Bruch’s membrane. The cases of successful rupture
were included in this study.
To  assess  the  antiangiogenic  activity  of
homoisoflavanone, we injected the mice intravitreously with
1  µM  homoisoflavanone  in  1  λ  PBS  10  days  after  laser
photocoagulation,  when  maximum  CNV  began.  These
experiments were repeated 27 times.
Qualitative assessment of choroidal neovascularization by
fluorescein  angiography:  Fourteen  days  after  laser
photocoagulation we perfused the anesthetized mice with an
intraperitoneal  injection  of  ketamine-xylazine  (10  mg/kg)
through  the  tail  vein  with  500,000  molecular  weight
fluorescein  conjugated  dextran  (Sigma–Aldrich  Ltd.,  St.
Louis, MO) dissolved in PBS. After 1 h perfusion the eyes of
euthanized  mice  were  enucleated  and  fixed  in  4%
paraformaldehyde for 4 h. The eyecups were dissected, flat-
mounted  in  Dako  mounting  medium  (DakoCytomation,
Glostrup, Denmark), and viewed by fluorescence microscopy
(BX50, Olympus, Tokyo, Japan) at a ×100 magnification.
Quantitative assessment of choroidal neovascularization by
counting vessels from subretinal fibrovascular membrane:
Fourteen days after laser photocoagulation, the eyes were
removed, fixed in 4% paraformaldehyde in 0.1 M phosphate
Figure 2. Effect of homoisoflavanone on fibroblast growth factor-2-
induced cell migration of human umbilical vein endothelial cells.
A: Each figure is representative of three independent experiments.
B: The basal migration of human umbilical vein endothelial cells
(HUVECs) that were left in serum-free media was normalized to
100% respectively. Each value represents means ± SEM from three
independent experiments (*p<0.05).
buffer for 24 h, and embedded in paraffin. Sagittal sections of
4–5 μm, each 10 μm apart, were cut through the center of the
laser-photocoagulation site. The sections were stained with
hematoxylin and eosin to assess CNV via light microscopy
(Carl  Zeiss,  Chester,  VA).  Any  vessels  from  subretinal
fibrovascular membrane were counted in five sections from
Figure 3. Effect of homoisoflavanone on laser-photocoagulation-
induced choroidal neovascularization. Choroidal neovascularization
(CNV) in control and homoisoflavanone-treated mice was evaluated
by  fluorescein  angiography  using  500,000  molecular  weight
fluorescein-conjugated  dextran.  Wholemount  preparation  from
control (A) and 1 µM homoisoflavanone-treated (B) mice subjected
to laser-photocoagulation-induced CNV was performed after 1 h
perfusion of fluorescein-conjugated dextran, respectively. Circles
indicate  CNV  in  the  laser-photocoagulation  site.  Hematoxylin-
stained cross-sections were prepared from control (C) and 1 μM
homoisoflavanone-treated (D) mice subjected to laser, respectively.
Arrows show the new vessels growing from choroidal vessels. E: To
quantify CNV, we counted vessels from subretinal fibrovascular
membrane. Data in each column are the mean ± standard deviation
values from 100 sites of 25 mice (*p<0.05). Scale bars in C and D
equal 50 µm.
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observers  blinded  to  treatment  (J.H.K.  and  K.H.P.).  The
average was calculated for over 100 sites of each group. There
were at least 25 animals in each group.
TUNEL  assay:  Ten  μM  homoisoflavanone  was
intravitreously injected into 7- to 8-week-old female C57BL/
6J mice. For negative control, 1 λ PBS was injected. The mice
of control or study group were sacrificed three days after 10
μM homoisoflavanone in 1 μl PBS injection or 1 μl PBS
injection, and enucleated. Enucleated globes were fixed in 4%
paraformaldehyde in 0.1 M phosphate buffer for 24 h and
embedded in paraffin. Terminal deoxynucleotidyl transferase
biotin-dUTP  nick  end  labeling  (TUNEL)  staining  was
performed with a kit (ApopTag Fluorescein Green; Intergen,
Purchase, NY), according to the manufacturer’s instructions.
TUNEL-positive cells were evaluated in randomly selected
fields at a ×400 magnification viewed under fluorescence
microscopy (BX50, Olympus).
Statistical  analysis: Statistical  differences  between  groups
were evaluated with the Student’s unpaired t-test (two-tailed).
Mean ± standard deviation was shown in figures. A p0.05 was
considered significant.
RESULTS
Effect  of  homoisoflavanone  on  tube  formation  of  human
umbilical vein endothelial cells: To investigate the effect of
homoisoflavanone  on  an  angiogenic  phenotype  of  tube
formation in vitro assay, we used FGF-2 as an angiogenic
factor. FGF-2 induced the formation of extensive capillary-
like  networks  of  HUVECs  cultured  on  two-dimensional
Figure 4. Effect of homoisoflavanone on the viability of human
umbilical  vein  endothelial  cells.  Various  concentrations  of
homoisoflavanone (1-10 μM) were treated on human umbilical vein
endothelial cells (HUVECs), and cells were incubated for two days.
Cell viability was measured by MTT assay. Each value represents
means ± SEM from three independent experiments (*p>0.05).
Matrigel matrix. This effect was almost completely inhibited
by co-treatment with homoisoflavanone (Figure 1A). FGF-2
stimulated tube formation of HUVECs approximately 1.4-
fold,  and  this  effect  was  abolished  by  homoisoflavanone
(Figure 1B).
Effect  of  homoisoflavanone  on  cell  migration  of  human
umbilical vein endothelial cells: Consistent with inhibition of
tube  formation,  FGF-2-induced  HUVECs  migration  was
blocked by homoisoflavanone (Figure 2A). FGF-2 increased
chemotactic  motility  of  HUVECs  approximately  1.3-fold,
which was nearly inhibited by homoisoflavanone (Figure 2B).
Effect  of  homoisoflavanone  on  laser-photocoagulation-
induced choroidal neovascularization: Based on our previous
data  of  inhibition  of  in  vivo  angiogenesis  of  chick
chorioallantoic  membrane  (CAM)  assay  and  retinal
Figure  5.  Retinal  toxicity  of  homoisoflavanone.  Ten  μM
homoisoflavanone was intravitreously injected, and the globes were
enucleated three days after treatment. The retina was normal without
any inflammatory cells in the vitreous, retina, or choroid. Compared
to  control,  TUNEL-positive  cells  were  not  increased  with
homoisoflavanone  injection.  Abbreviations:  ganglion  cell  layer
(GCL); inner nuclear layer (INL); outer nuclear layer (ONL). Scale
bars equal 50 µm.
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559angiogenesis  without  toxicity  [7,8],  we  injected  1  μM
homoisoflavanone in 1 μl PBS intravitreously, 10 days after
laser  photocoagulation  when  active  neovascularization
occurs. To assess CNV qualitatively, fluorescein angiography
using fluorescein-conjugated dextran was performed. Retinas
from control mice subjected to laser photocoagulation showed
CNV with diffuse leakage on the laser photocoagulation site
(Figure  3A).  In  contrast,  retinas  from  homoisoflavanone-
treated  mice  showed  significantly  reduced  CNV  and  its
leakage (Figure 3B). To quantify CNV, we counted, in a
masked  fashion,  vessels  from  subretinal  fibrovascular
membrane. The vessels were defined as the mean number per
section found in five sections per laser photocoagulation site.
Retinas  from  control  mice  demonstrated  multiple  CNV
patches (Figure 3C), whereas retinas from homoisoflavanone-
treated mice showed significantly fewer neovascular lumens
(Figure  3D).  We  found  that  homoisoflavanone-injected
groups  had  a  significant  decrease  of  CNV  compared  to
controls (Figure 3E).
Effect  of  homoisoflavanone  on  the  viability  of  human
umbilical  vein  endothelial  cells:  To  investigate  cytotoxic
effect of homoisoflavanone on HUVECs, we performed MTT
assay in various concentrations of homoisoflavanone (1-10
μM).  The  viability  of  homoisoflavanone-treated  HUVECs
was not affected up to 10 μM (Figure 4).
Retinal  toxicity  of  homoisoflavanone:  Retinal  toxicity  on
intravitreal  injection  of  10  μM  homoisoflavanone  was
evaluated  through  histological  examination  and  TUNEL
assay. As demonstrated in Figure 5, the retina was of normal
thickness,  and  all  retinal  layers  were  clear  without  any
inflammatory  cells  in  the  vitreous,  retina,  or  choroid.
Compared  to  control,  TUNEL-positive  cells  were  not
increased with homoisoflavanone injection.
DISCUSSION
We  first  isolated  homoisoflavanone  from  the  bulb  of
Cremastra appendiculata, which has been traditionally used
in Korea to prevent tumor metastasis, and found it to be an
angiogenesis  inhibitor  through  inhibitory  activity  against
proliferation of HUVECs [7]. Previously, we demonstrated
homoisoflavanone  inhibits  in  vivo  angiogenesis  of
chorioallantoic membrane of chick embryo [7] and retinal
angiogenesis [8]. CNV and vascular leakage are two main
causes of serious visual loss in AMD. We presented in this
study significant inhibitory effect of homoisoflavanone on
CNV. Homoisoflavanone reduced the incidence of clinically
significant  vascular  leakage  in  an  experimental  model  of
CNV,  which  was  consistent  with  histologic  findings  of  a
significantly lower number of CNV in homoisoflavanone-
treated group.
The  blood  vessel  growth  in  CNV  correlates  with  the
expression of vascular endothelial growth factor, FGF-2, and
their  receptors  [10].  We  showed  that  homoisoflavanone
significantly inhibits FGF-2-induced tube formation and cell
invasion  of  HUVECs.  Previously,  we  revealed  that  G2/M
phase cell cycle arrest, which is associated with the increase
of p21WAF1 expression, caused the antiproliferative activity of
homoisoflavanone  on  HUVECs  [8].  In  addition,
homoisoflavanone  showed  no  effect  on  cell  viability  of
HUVECs,  and  no  retinal  toxicity  up  to  10  μM  which  is
equivalent to 10 times of effective therapeutic dose (1 μM) to
CNV.  Based  on  these  results,  it  is  possible  that
homoisoflavanone  may  attenuate  laser-photocoagulation-
induced CNV through a direct antiangiogenic effect without
cytotoxic effect in a therapeutic range (1-10 μM).
Given the well documented antiproliferative effect on
HUVECs and antiangiogenic effect on and CNV in this study,
homoisoflavanone,  extracted  from  the  bulb  of  Cremastra
appendiculata,  could  be  a  new  antiangiogenic  agent  for
treatment of CNV. Furthermore, homoisoflavanone could be
also applied to other vasoproliferative retinopathies, such as
diabetic retinopathy, and tumors including retinoblastoma.
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